Open source pharma and its developmental potential
DOI:
https://doi.org/10.18617/liinc.v14i1.4144Abstract
ABSTRACT Open Source Pharma (OSP) stands out as an innovative way to re-align pharmaceutical research with health needs, in particular to find solutions to poverty-related infectious diseases. OSP means open collaboration, to open access to data and other results, and open licenses for sharing and distribution of research outcomes. This paper provides an exploratory analysis of OSP current practices and business models, based on literature review and one in-depth interview with Matthew Todd, leader of the Open Source Malaria project. We claim that OSP may become a working and more promising alternative to traditional pharma as long as it is supported by public policy so as to fully emerge and visibilise its benefits.
Keywords: Open Source Pharma; Poverty-related infectious diseases; open science; public health; drug discovery.
Downloads
Additional Files
Published
Issue
Section
License
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant Liinc em Revista the right of first publication with the work simultaneously licensed under a Creative Commons Attribution 4.0 International License.
The authors have permission and are encouraged to deposit their manuscripts and versios of record (VoR) in their personal web pages or institutional repositories, generic repositories etc., before (pre-print) or after (post-print) the publication in Liinc em Revista, according to its open access depositing policy registered in the Directory of Editorial Policies of Brazilian Journals (DIADORIM), kindly providing a link to the article published on Liinc's website.
Liinc em Revista, published by Instituto Brasileiro de Informação em Ciência e Tecnologia, is licensed under a Creative Commons Attribution 4.0 International License – CC BY 4.0 
